Adverum Biotechnologies Inc Total Assets
Adverum Biotechnologies Inc total assets. Based on the latest financial reports, Adverum Biotechnologies Inc (ADVM) holds total assets worth $72.40 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Adverum Biotechnologies Inc (ADVM) total market value for the company's overall valuation and market capitalisation.
Total Assets of Adverum Biotechnologies Inc (2012–2024)
Total assets of Adverum Biotechnologies Inc from 2012 to 2024. This chart illustrates how Adverum Biotechnologies Inc's total assets have evolved over time, based on quarterly financial data. See Adverum Biotechnologies Inc share price for real-time trading data and today's change.
Adverum Biotechnologies Inc - Asset Composition Analysis
Adverum Biotechnologies Inc Total Assets Breakdown (December 2024)
Adverum Biotechnologies Inc total assets breakdown as of December 2024. Adverum Biotechnologies Inc's total assets of $72.40 Million consist of 73.0% current assets and 27.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 33.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Adverum Biotechnologies Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore ADVM net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Adverum Biotechnologies Inc's current assets represent 73.0% of total assets in 2024, a decrease from 99.0% in 2012.
- Cash Position: Cash and equivalents constituted 33.7% of total assets in 2024, down from 92.5% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Adverum Biotechnologies Inc Competitors by Total Assets
Key competitors of Adverum Biotechnologies Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Adverum Biotechnologies Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.65 | 5.82 | 20.82 |
| Quick Ratio | 0.65 | 5.82 | 20.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-15.84 Million | $133.42 Million | $413.57 Million |
Adverum Biotechnologies Inc - Advanced Valuation Insights
This section examines the relationship between Adverum Biotechnologies Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.93 |
| Latest Market Cap to Assets Ratio | 0.54 |
| Asset Growth Rate (YoY) | 15.5% |
| Total Assets | $179.84 Million |
| Market Capitalization | $96.26 Million USD |
Valuation Analysis
Below Book Valuation: The market values Adverum Biotechnologies Inc's assets below their book value (0.54x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Adverum Biotechnologies Inc's assets grew by 15.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Adverum Biotechnologies Inc (2012–2024)
The table below shows the annual total assets of Adverum Biotechnologies Inc from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $179.84 Million | +15.45% |
| 2023-12-31 | $155.77 Million | -49.49% |
| 2022-12-31 | $308.37 Million | -29.87% |
| 2021-12-31 | $439.73 Million | -8.88% |
| 2020-12-31 | $482.57 Million | +116.66% |
| 2019-12-31 | $222.73 Million | +4.32% |
| 2018-12-31 | $213.50 Million | +5.74% |
| 2017-12-31 | $201.91 Million | -13.93% |
| 2016-12-31 | $234.58 Million | -11.25% |
| 2015-12-31 | $264.32 Million | +63.25% |
| 2014-12-31 | $161.91 Million | +14822.21% |
| 2013-12-31 | $1.08 Million | +181.09% |
| 2012-12-31 | $386.00K | -- |
About Adverum Biotechnologies Inc
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is … Read more